SHL Medical, a global leader in the design, development, and
manufacturing of advanced autoinjector solutions, has officially
inaugurated its new state-of-the-art manufacturing facility in North
Charleston, South Carolina.
This strategic expansion marks a significant milestone in the Swiss-based company’s global growth,
reinforcing its commitment to meeting the increasing worldwide demand
for autoinjectors, most notably used in the cardiometabolic sector.
The new facility will manufacture SHL Medical’s industry-leading
autoinjectors, which are used in some of the world’s best-selling
medications in areas such as endocrine and metabolic disorders
(including GLP-1 therapies), dermatology, musculoskeletal diseases,
and other therapy areas. It ensures a reliable supply of these
critical devices to millions of patients worldwide.
SHL Medical is significantly increasing its production capacity to
meet growing demand in North America while strengthening supply chain
resilience.
“US-based production is a major step forward in our
global expansion and reinforces our position as the leader in
providing end-to-end drug delivery solutions,” said Ulrich Faessler,
CEO & Chairman of SHL Medical. “With our established site in Taiwan
and the upcoming facility in Switzerland, we will be the only
autoinjector manufacturer operating across three continents, bringing us even closer to our customers.”
The fully automatised 360,000 ft facility represents a 220 million USD
investment and has already created over 300 local jobs, contributing
to the economic growth of the region.
Equipped with cutting-edge
medical device injection moulding technology and fully automated
assembly capabilities, the site ensures unmatched precision,
efficiency, and quality in SHL Medical’s advanced drug delivery
solutions.
By leveraging its existing final assembly, labeling, and packaging
operations in Deerfield Beach, Florida, and integrating recent
acquisitions under SHL Advantec, the North Charleston facility
enhances SHL Medical’s US presence and solidifies its leadership in
large-scale autoinjector production. The company is on track to
deliver 1.5 billion devices to customers in 2025.
“The most trusted autoinjector brand is now made in the USA. We are
proud to be contributing to the growth of the local economy and
becoming a key player in the area while contributing to our
sustainability goals.” adds Kimberlee Steele, Managing Director North
America at SHL Medical.
The Grand Opening event, attended by approximately 180 guests,
including South Carolina’s Governor Henry McMaster and Swiss Embassy
Consul General Urs Broennimann, marked the official opening of SHL
Medical’s innovative autoinjector production in the United States.
